Company Description
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
The company’s lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration.
It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company’s NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine.
The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.
Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jeffrey Frelick |
Contact Details
Address: 2 Burlington Woods Drive, Suite 100 Burlington, Massachusetts 01803 United States | |
| Phone | 781 552 4452 |
| Website | bonebiologics.com |
Stock Details
| Ticker Symbol | BBLGW |
| Exchange | NASDAQ |
| Stock Type | Warrants |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419554 |
| CUSIP Number | 098070113 |
| ISIN Number | US0980701546 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Frelick | Chief Executive Officer and President |
| Deina H. Walsh C.P.A. | Chief Financial Officer |